因卵巢癌接受双侧卵巢切除术的绝经前女性的激素替代治疗——一项全国性人群基础研究
瑞典全国性登记队列研究纳入2008至2014年间因上皮性卵巢癌、非上皮性卵巢癌或交界性卵巢肿瘤接受双侧输卵管卵巢切除术的18-50岁女性664例,分析术后激素替代治疗(HRT)配药情况。术后前五年总体HRT配药率为32%-41%,多数绝经前女性术后未使用HRT;年龄<40岁(OR 6.17)和40-44岁(OR 2.95)及交界性肿瘤组织学(OR 3.84)与HRT配药显著相关。
要点
- 术后前五年总队列HRT配药率为32%-41%。
- 术后0.5-1年,<40岁女性51%配药HRT,≥40岁女性为25%。
- 上皮性卵巢癌女性术后0.5-1年仅21%配药HRT。
核心结论
- 多数因卵巢癌接受双侧输卵管卵巢切除术的绝经前女性术后未使用HRT。
- 作者认为需要关注年轻女性卵巢癌治疗后的HRT使用,以预防疾病负担和较差的生活质量。
研究设计与样本
- 全国性人群和登记为基础的队列研究,纳入2008至2014年间在瑞典妇科癌症质量登记处(SQRGC)登记、因上皮性卵巢癌(EOC)、非上皮性卵巢癌(NEOC)或交界性卵巢肿瘤(BOT)接受双侧输卵管卵巢切除术(BSOE)的18-50岁女性。
- HRT配药数据来自国家处方药登记处,从手术至2015年12月随访结束,按半年度间隔分析,包括逻辑回归分析。
- 共识别664例卵巢癌女性,其中EOC 396例、NEOC 61例、BOT 207例;手术时49%的女性≤44岁。
主要发现
- 术后前五年,总队列HRT配药率在32%至41%之间波动。
- 术后0.5-1年随访期间,<40岁女性中51%配药HRT,≥40岁女性中25%配药HRT。
- EOC女性中,术后0.5-1年21%配药HRT。
- 多变量回归分析显示,年龄<40岁(OR 6.17,p<0.001)、年龄40-44岁(OR 2.95,p<0.001)以及BOT组织学(OR 3.84,p<0.001)是HRT配药的显著变量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To study the extent of hormone replacement therapy (HRT) dispensing in premenopausal women after being treated with bilateral salpingo-oophorectomy (BSOE) for ovarian cancer (OC). METHODS: Nationwide population- and register-based cohort study including women 18-50 years old, registered in The Swedish Quality Register for Gynecological Cancer (SQRGC), where BSOE was performed due to epithelial (EOC) and non-epithelial ovarian cancers (NEOC) or borderline ovarian tumor (BOT) between 2008 and 2014. Data on HRT dispensing was obtained from the National Prescribed Drug Register analyzed at semi-annual intervals from surgery until end of follow-up December 2015, including a logistic regression analysis. RESULTS: A cohort of 664 women were identified with OC, whereas 396 women had an EOC, 61 a NEOC and 207 a BOT. At surgery 49% of the women were ≤44 years. HRT dispensed to the total cohort varied between 32% and 41% the first five years after surgery. During follow-up at first 0.5-1 year 51% of the women <40 years were dispensed HRT compared to 25% of women ≥40 years. Of women with EOC, 21% dispensed HRT at first 0.5-1 year. In the multivariable regression analysis; age <40 (OR6.17, p < 0.001) and age 40-44 (OR2.95, p < 0.001) as well as BOT histology (OR3.84, p < 0.001) were found significant variables for dispensing of HRT. CONCLUSION: A majority of premenopausal women undergoing BSOE for OC did not use HRT postoperatively. Our study shows that there is a need to address HRT use after OC treatment in young women to prevent from morbidity and a poorer quality of life.
引用
- von Kartaschew ÅE, Dahm-Kähler P, Rodriguez-Wallberg KA, et al. Hormone replacement in premenopausal women treated with bilateral oophorectomy for ovarian cancer - a nationwide population-based study. Gynecol Oncol. 2022. PMID: 36216625. doi:10.1016/j.ygyno.2022.09.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。